PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells
Authors:
Open Access
- 1 January 2010
- journal article
- research article
- Published by Wiley in International Journal of Cell Biology
- Vol. 2010, 1-10
Abstract
Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC inhibitor, require caspase-8 and the adaptor molecule, Fas-associated death domain (FADD), in acute leukemia cells. PCI-24781 treatment also causes an increase in superoxide levels, which has been reported for other HDACi. However, an antioxidant does not reverse histone alterations caused by PCI-24781, indicating that ROS generation is likely downstream of the effects that PCI-24781 exerts on histone H3. Taken together, these results provide insight into the mechanism of apoptosis induction by PCI-24781 in leukemia by highlighting the roles of caspase-8, FADD and increased superoxide levels.Keywords
Funding Information
- National Institutes of Health (RO1 CA 115811)
- National Cancer Institute (RO1 CA 115811)
- Center for Cancer Epigenetics (RO1 CA 115811)
This publication has 23 references indexed in Scilit:
- The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyBlood, 2009
- PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma CellsClinical Cancer Research, 2009
- Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cellsBlood, 2009
- Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic ProteinsMolecular Medicine, 2008
- Phenotypic plasticity and the epigenetics of human diseaseNature, 2007
- CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2006
- The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cellsLeukemia, 2004
- FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cellsOncogene, 2003
- Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cellsBlood, 2003
- Apoptotic Release of Histones from NucleosomesJournal of Biological Chemistry, 2002